gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1571Research ArticleНОВОСТИ КОЛОПРОКТОЛОГИИNEWS OF COLOPROCTOLOGYСодержание пируваткиназы типа М2 (М2-РК) в плазме крови больных воспалительными заболеваниями толстой кишкиContents of plasma М2-pyruvate kinase (M2-РК) in patients with inflammatory bowel diseasesКоновичЕ. А.KonovichYe. A.ХалифИ. Л.KhalifI. L.Государственный научный центр колопроктологии РосмедтехнологийRussian Federation2010021120102057579Copyright © Конович Е.А., Халиф И.Л., 20102010Конович Е.А., Халиф И.Л.Konovich Y.A., Khalif I.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1571

Цель исследования. Определение уровня М2пируваткиназы (М2-РК) у больных язвенным колитом (ЯК) и болезнью Крона (БК) и его зависимости от характера течения и клинико-эндоскопической активности заболевания.Материал и методы. Обследованы 70 пациентов: 42 – с ЯК, 15 – с БК, 13 – с синдромом раздраженного кишечника (СРК) и 10 здоровых лиц. Концентрацию М2-РК в плазме крови определяли твердофазным сэндвич методом иммуноферментного анализа с использованием тест-систем фирмы «ScheBo» (Германия).Результаты. Уровень М2-РК у больных ЯК, БК, СРК и здоровых лиц составил соответственно 29,1±3,0, 17,3±1,5, 7,9±1,6 и 7,0±1,5 ед./мл (р<0,05 – для ЯК и БК в сравнении с СРК и контрольной группой и для ЯК в сравнении с БК). Уровень М2-РК значительно повышался у больных с тяжелой (45,9±6,4 ед./мл) и среднетяжелой (20,9±3,2 ед./мл) формами ЯК, включая пациентов, резистентных к стероидной терапии (61,5±6,2 ед./мл), по сравнению с больными в стадии ремиссии (11,0±1,8 ед./мл, р<0,05) и у пациентов с хроническим непрерывным течением по сравнению с хроническим рецидивирующим течением (40,3±5,0 и 22,7±3,8 ед./мл, р<0,05). Уровень М2-РК имел выраженную тенденцию к повышению с усилением эндоскопической активности ЯК.Увеличение концентрации М2-РК (М±σ контрольной группы, р<0,05) наблюдалось у 76,2% больных ЯК, у 73,3% больных БК и у 15,4% пациентов с СРК.Выводы. Содержание М2-РК в крови больных ЯК и БК значительно возрастает. Повышение уровня М2-РК у больных ЯК ассоциировано с усилением клинико-эндоскопической активности, хроническим непрерывным течением и резистентностью к стероидной терапии.

Aim of investigation

Aim of investigation. Assessment of М2-pyruvate kinase level (M2-РК) at patients with ulcerative colitis (UC) and Crohn’s disease (CD) and its relation to course, clinical and endoscopical activity of disease.

Material and methods

Material and methods. Overall 70 patients were investigated: 42 – with UC, 15 – with CD, 13 – with irritable bowel syndrome (IBS) and 10 healthy patients. Blood plasma concentration of M2-РК was determined by solid-phase sandwich method of enzyme-linked immunoassay with application of «ScheBo» (Germany) test-systems.

Results

Results. The level of M2-РК in patients with UC, CD, IBS and healthy persons was 29,1±3,0, 17,3±1,5, 7,9±1,6 and 7,0±1,5 U/ml respectively (р<0,05 – for UC and CD in comparison to IBS and control group and for UC in comparison to CD). The level of M2-РК considerably raised in patients with severe (45,9±6,4 U/ml) and moderate (20,9±3,2 U/ml) UC, including steroid-resistant patients (61,5±6,2 U/ml), in comparison to patients in remission (11,0±1,8 U/ml, р><0,05) and at patients with chronic continuous course in comparison to chronic relapsing course (40,3±5,0 and 22,7±3,8 U/ml, р><0,05). The level of M2-РК had the strong tendency to increase with progression of endoscopic activity of UC. Increase of M2-РК concentration (М±σ of the control group, р><0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.>< 0,05 – for UC and CD in comparison to IBS and control group and for UC in comparison to CD). The level of M2-РК considerably raised in patients with severe (45,9±6,4 U/ml) and moderate (20,9±3,2 U/ml) UC, including steroid-resistant patients (61,5±6,2 U/ml), in comparison to patients in remission (11,0±1,8 U/ml, р<0,05) and at patients with chronic continuous course in comparison to chronic relapsing course (40,3±5,0 and 22,7±3,8 U/ml, р><0,05). The level of M2-РК had the strong tendency to increase with progression of endoscopic activity of UC. Increase of M2-РК concentration (М±σ of the control group, р><0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.>< 0,05) and at patients with chronic continuous course in comparison to chronic relapsing course (40,3±5,0 and 22,7±3,8 U/ml, р< 0,05). The level of M2-РК had the strong tendency to increase with progression of endoscopic activity of UC. Increase of M2-РК concentration (М±σ of the control group, р<0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.>< 0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.

Conclusions

Conclusions. Blood level of M2-РК of patients with UC and CD increases considerably. Elevation of M2-РК level at patients with UC is associated to enhancement of clinical and endoscopical activity, chronic continuous course and steroid-resistance.

язвенный колитболезнь КронаМ2-пируваткиназаulcerative colitisCrohn’s diseaseМ2- pyruvate kinaseReferencesМихайлова Т.Л., Халиф И.Л. Язвенный колит. Болезнь Крона. Клиническая характеристика // Неспецифические воспалительные заболевания кишечника / Под ред. Г.И. Воробьева, И.Л. Халифа.– М.: Миклош, 2008. – C. 136–155.Михайлова Т.Л., Халиф И.Л. Язвенный колит. Болезнь Крона. Клиническая характеристика // Неспецифические воспалительные заболевания кишечника / Под ред. Г.И. Воробьева, И.Л. Халифа.– М.: Миклош, 2008. – C. 136–155.Сергеева Н.С., Мишунина М.П., Хомяков В.М. и др. Динамика содержания в плазме крови опухолевой пируваткиназы М2-типа (TuM2-PK) на этапах диагностики, лечения и мониторинга больных колоректальным раком // Рос. онкол. журн. – 2007. – № 5. – C. 9–12.Сергеева Н.С., Мишунина М.П., Хомяков В.М. и др. Динамика содержания в плазме крови опухолевой пируваткиназы М2-типа (TuM2-PK) на этапах диагностики, лечения и мониторинга больных колоректальным раком // Рос. онкол. журн. – 2007. – № 5. – C. 9–12.Cerwenca H., Aigner R., Bacher H. et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions // Anticancer Res. – 1999. – Vol. 19. – P.849–852.Cerwenca H., Aigner R., Bacher H. et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions // Anticancer Res. – 1999. – Vol. 19. – P.849–852.Chung-Faye G., Hayee B., Maestranzi S. et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation // Inflamm. Bowel Dis. – 2007. – Vol. 13.– P. 1374–1378.Chung-Faye G., Hayee B., Maestranzi S. et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation // Inflamm. Bowel Dis. – 2007. – Vol. 13.– P. 1374–1378.Czub E., Herzig K.H., Szaflarska-Popawska A. et al. Fecal pyruvate kinase:a potential new marker for intestinal inflammation in chidren with inflammatory bowel disease // Scand. J. Gastroenterol. – 2007. – Vol. 42, N 10. – P. 1147–1150.Czub E., Herzig K.H., Szaflarska-Popawska A. et al. Fecal pyruvate kinase:a potential new marker for intestinal inflammation in chidren with inflammatory bowel disease // Scand. J. Gastroenterol. – 2007. – Vol. 42, N 10. – P. 1147–1150.Eigenbrodt E., Reinacher M., Scheefers-Borchel U. et al. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells // Critical Rev. Oncogenesis. – 1992. – Vol. 3. – P. 91–115.Eigenbrodt E., Reinacher M., Scheefers-Borchel U. et al. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells // Critical Rev. Oncogenesis. – 1992. – Vol. 3. – P. 91–115.Ewald T., Toepler M., Akinci A. et al. Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data // Z.Gastroenterol. – 2005. – Vol. 43, N 12. – P. 1313–1317.Ewald T., Toepler M., Akinci A. et al. Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data // Z.Gastroenterol. – 2005. – Vol. 43, N 12. – P. 1313–1317.Hang U., Hundt S., Brenner H. Sensitivity and specificity of faecal tumour M2-pyruvate kinase for detection of colorectal adenomas in a large screening study // Br. J. Cancer. – 2008. – Vol. 99, N 1. – P. 133–135.Hang U., Hundt S., Brenner H. Sensitivity and specificity of faecal tumour M2-pyruvate kinase for detection of colorectal adenomas in a large screening study // Br. J. Cancer. – 2008. – Vol. 99, N 1. – P. 133–135.Ibsen K.H., Orlando R.A., Garrat K.N. et al. Expression of multimolecular forms of pyruvate kinase in normal, benign and malignant human breast tissue // Cancer Res. – 1982. – Vol. 42. – P. 888–892.Ibsen K.H., Orlando R.A., Garrat K.N. et al. Expression of multimolecular forms of pyruvate kinase in normal, benign and malignant human breast tissue // Cancer Res. – 1982. – Vol. 42. – P. 888–892.Izcue A., Coombes J.L., Powrie F. Regulatory lymphocytes and intestinal Inflammation // Annu. Rev. Immunol. – 2009. – Vol. 27. – P. 313–338.Izcue A., Coombes J.L., Powrie F. Regulatory lymphocytes and intestinal Inflammation // Annu. Rev. Immunol. – 2009. – Vol. 27. – P. 313–338.Jeffery J., Lewis S.J., Ayling R.M. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders// Inflamm. Bowel Dis. – 2009. – Vol. 15, N 11. – P. 1630–1634.Jeffery J., Lewis S.J., Ayling R.M. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders// Inflamm. Bowel Dis. – 2009. – Vol. 15, N 11. – P. 1630–1634.Johnson M.W., Maestranzi S., Duffy A.M. et al. Faecal M2-pyruvate kinase: a novel noninvasive marker of ileal pouch inflammation // Eur. J. Gastroenterol. Hepatol. – 2009. – Vol. 21, N 5. – P. 544–550.Johnson M.W., Maestranzi S., Duffy A.M. et al. Faecal M2-pyruvate kinase: a novel noninvasive marker of ileal pouch inflammation // Eur. J. Gastroenterol. Hepatol. – 2009. – Vol. 21, N 5. – P. 544–550.Kobayashi T., Okamoto S., Hisamatsu T. et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn′s disease // Gut. – 2008. – Vol. 57. – P. 1682–1689.Kobayashi T., Okamoto S., Hisamatsu T. et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn′s disease // Gut. – 2008. – Vol. 57. – P. 1682–1689.Luftner D., Mesterharm J., Akrivakis C. et al. Tumor Type M2-pyruvate kinase expression in advanced breast cancer // Anticancer Res. – 2000. – Vol. 20. – P. 5077–5082.Luftner D., Mesterharm J., Akrivakis C. et al. Tumor Type M2-pyruvate kinase expression in advanced breast cancer // Anticancer Res. – 2000. – Vol. 20. – P. 5077–5082.Mazurek S., Grimm H., Oehmke M. et al. Tumor M2PK and glutaminolytiс enzymes in the metabolic shift of tumor cells // Anticancer Res. – 2000. – Vol. 20. – P. 5151–5154.Mazurek S., Grimm H., Oehmke M. et al. Tumor M2PK and glutaminolytiс enzymes in the metabolic shift of tumor cells // Anticancer Res. – 2000. – Vol. 20. – P. 5151–5154.Oremek G., Muller R., Sapoutzis N., Wigand R. Pyruvate kinase type tumor M2 plasma levels in patients afflicted with rheumatic diseases // Anticancer Res. – 2003. – Vol. 23. – P. 1131–1134.Oremek G., Muller R., Sapoutzis N., Wigand R. Pyruvate kinase type tumor M2 plasma levels in patients afflicted with rheumatic diseases // Anticancer Res. – 2003. – Vol. 23. – P. 1131–1134.Oremek G., Rutner F., Sapoutzis N., Sauer-Eppel H. Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathy // Anticancer Res. – 2003. – Vol. 23. – P. 1155–1158.Oremek G., Rutner F., Sapoutzis N., Sauer-Eppel H. Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathy // Anticancer Res. – 2003. – Vol. 23. – P. 1155–1158.Oremek G., Sapoutzis N., Kramer W. et al. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma // Anticancer Res. – 2000. – Vol. 20. – P. 5095– 5098.Oremek G., Sapoutzis N., Kramer W. et al. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma // Anticancer Res. – 2000. – Vol. 20. – P. 5095– 5098.Rakoff-Nahoum S., Hao L., Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis // Immunity. – 2006. – Vol. 25. – P. 319–329.Rakoff-Nahoum S., Hao L., Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis // Immunity. – 2006. – Vol. 25. – P. 319–329.Schneider J., Morr H., Velcovsky H. et al. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases // Cancer Detect. Prev. – 2000. – Vol. 24, N 6. – P. 531–535.Schneider J., Morr H., Velcovsky H. et al. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases // Cancer Detect. Prev. – 2000. – Vol. 24, N 6. – P. 531–535.Schneider J., Velcovsky H., Morr H. et al. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 211, NCE and SCC in the diagnosis of lung cancer // Anticancer Res. – 2000. – Vol. 20. – P. 5053–5058.Schneider J., Velcovsky H., Morr H. et al. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 211, NCE and SCC in the diagnosis of lung cancer // Anticancer Res. – 2000. – Vol. 20. – P. 5053–5058.Shih D.Q., Targan S.R. Immunopathogenesis of inflammatory bowel disease // World J. Gastroenterol. – 2008. – Vol. 14. – P. 390–400.Shih D.Q., Targan S.R. Immunopathogenesis of inflammatory bowel disease // World J. Gastroenterol. – 2008. – Vol. 14. – P. 390–400.Staib P., Hoffmann M., Schinkothe T. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors // Clin. Chem. Lab. Med. – 2006. – Vol. 44, N 1. – P. 28–31.Staib P., Hoffmann M., Schinkothe T. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors // Clin. Chem. Lab. Med. – 2006. – Vol. 44, N 1. – P. 28–31.Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease // J. Clin. Invest. – 2007. – Vol. 117. – P. 514–521.Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease // J. Clin. Invest. – 2007. – Vol. 117. – P. 514–521.Walkowiak J., Banasiewicz T., Krokowicz P. et al. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis // Scand. J. Gastroenterol. – 2005. – Vol. 40, N 12. – P. 1493–1494.Walkowiak J., Banasiewicz T., Krokowicz P. et al. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis // Scand. J. Gastroenterol. – 2005. – Vol. 40, N 12. – P. 1493–1494.Zenewicz L.A., Antov A., Flawell R.A. CD4 T-cell differentiation and Inflammatory bowel disease // Trends Mol. Med. – 2009. – Vol. 15. – P. 199–207.Zenewicz L.A., Antov A., Flawell R.A. CD4 T-cell differentiation and Inflammatory bowel disease // Trends Mol. Med. – 2009. – Vol. 15. – P. 199–207.

The authors declare that there are no conflicts of interest present.